IGF1R and cancer: Researchers have also found that the differentiation of ex vivo-expanded CD34+ cells through manipulation of RAS/MAPK, IGF-1R, and TGF-β signaling pathways is an efficient approach for generating functional NK cells that can be used for cancer immunotherapy (8).